更新于：2024-12-17
Aripiprazole
阿立哌唑
更新于：2024-12-17
概要
基本信息
简介阿立哌唑，商品名 Abilify Discmelt®，是一种非典型抗精神病药物，用于治疗多种情绪和精神病，包括但不限于精神分裂症、I 型双相情感障碍、重度抑郁症、易激惹相关疾病、自闭症和图雷特综合症。作用机制为5-HT2A 激动剂和 D2 受体激动剂。阿立哌唑于2002 年首次获得美国 FDA 批准，由大冢控股开发。它的主要适应症是用于治疗精神分裂症。 |
药物类型 小分子化药 |
别名 ABILIFY MAINTENA、Abilify MyCite、Abilify Prolonged Release Aqueous Suspension + [30] |
作用机制 5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor激动剂(多巴胺D2受体激动剂) |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-11-15), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C23H27Cl2N3O2 |
InChIKeyCEUORZQYGODEFX-UHFFFAOYSA-N |
CAS号129722-12-9 |
关联
510
项与 阿立哌唑 相关的临床试验An Open-Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Multiple-Dose, Steady-State, Fully Replicate, Crossover Bioequivalence Study of Aripiprazole 400 mg Powder and Solvent for Prolonged-Release Suspension for Injection and Abilify Maintena® 400 mg Powder and Solvent for Prolonged-Release Suspension for Injection in Adult Patients withSchizophrenia under Fasting Condition. - NIL
The Effectiveness of Aripiprazole augmentation in Major depressive disorder patients with Symptom of Anxious distress (TEAMS-Anxious distress)
To study the efficacy and safety of aripiprazole and Ondansetron augmentation among obsessive-compulsive Disorder patients undergoing standard treatment. - NIL
100 项与 阿立哌唑 相关的临床结果
登录后查看更多信息
100 项与 阿立哌唑 相关的转化医学
登录后查看更多信息
100 项与 阿立哌唑 相关的专利（医药）
登录后查看更多信息
5,688
项与 阿立哌唑 相关的文献（医药）2025-01-01ACTA PSYCHIATRICA SCANDINAVICA
Dosing levels of antipsychotics and mood stabilizers in bipolar disorder: A Nationwide cohort study on relapse risk and treatment safety
Article
作者: Lähteenvuo, Markku ; Tanskanen, Antti ; Hamina, Aleksi ; Taipale, Heidi ; Lintunen, Jonne ; Paljärvi, Tapio ; Tiihonen, Jari
Abstract:
Background:
Finding effective treatment regimens for bipolar disorder is challenging, as many patients suffer from significant symptoms despite treatment. This study investigated the risk of relapse (psychiatric hospitalization) and treatment safety (non‐psychiatric hospitalization) associated with different doses of antipsychotics and mood stabilizers in persons with bipolar disorder.
Methods:
Individuals aged 15–65 with bipolar disorder were identified from Finnish national health registers in 1996–2018. Studied antipsychotics included olanzapine, risperidone, quetiapine, aripiprazole; mood stabilizers lithium, valproic acid, lamotrigine, and carbamazepine. Medication use was divided into three time‐varying dose categories: low, standard, and high. The studied outcomes were risk of psychiatric hospitalization (relapse) and the risk of non‐psychiatric hospitalization (treatment safety). Stratified Cox regression in within‐individual design was used.
Results:
The cohort included 60,045 individuals (mean age 41.7 years, SD 15.8; 56.4% female). Mean follow‐up was 8.3 years (SD 5.8). Of antipsychotics, olanzapine and aripiprazole were associated with a decreased risk of relapse in low and standard doses, and risperidone in low dose. The lowest adjusted hazard ratio (aHR) was observed for standard dose aripiprazole (aHR 0.68, 95% CI 0.57–0.82). Quetiapine was not associated with a decreased risk of relapse at any dose. Mood stabilizers were associated with a decreased risk of relapse in low and standard doses; lowest aHR was observed for standard dose lithium (aHR 0.61, 95% CI 0.56–0.65). Apart from lithium, high doses of antipsychotics and mood stabilizers were associated with an increased risk of non‐psychiatric hospitalization. Lithium was associated with a decreased risk of non‐psychiatric hospitalization in low (aHR 0.88, 95% CI 0.84–0.93) and standard doses (aHR 0.81, 95% CI 0.74–0.88).
Conclusions:
Standard doses of lithium and aripiprazole were associated with the lowest risk of relapse, and standard dose of lithium with the lowest risk of non‐psychiatric hospitalization. Quetiapine was not associated with decreased risk of relapse at any dose.
2025-01-01PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective
Article
作者: Corkery, J ; Floresta, G ; Chiappini, S ; Martinotti, G ; Mosca, A ; Arillotta, D ; Papanti, G D ; Schifano, F ; Semeraro, F ; D'Andrea, G ; Schifano, N ; Guirguis, A
Intranasal esketamine, approved with oral antidepressants for adults with treatment-resistant depression (TRD), is the S-enantiomer of ketamine and has higher potency and affinity for N-Methyl-d-Aspartate receptors. Administered intranasally, it offers rapid absorption and onset, essential for severe depressive symptoms or suicidal impulses. Comparative studies on esketamine and ketamine's urological safety profiles show esketamine has lower or comparable risks of renal and urinary disorders. Ketamine, however, has documented cases of nephrotoxicity and severe urological issues in recreational users. The study aims to further evaluate and compare these profiles against other antidepressants and antipsychotics using the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) data. ADR cases were reported to the FDA up to May 12, 2024, being drugs listed including esketamine, ketamine, quetiapine, aripiprazole, olanzapine, risperidone, citalopram, escitalopram, paroxetine, fluoxetine, sertraline, duloxetine, venlafaxine, amitriptyline, and clomipramine. Risperidone showed the highest ADRs (107,418) and serious cases (71,515), with significant renal and urinary disorders reported, including acute kidney injury and urinary incontinence. Olanzapine, quetiapine, and aripiprazole also had high serious ADRs. Venlafaxine and fluoxetine were notable among antidepressants for acute kidney injury. Esketamine and ketamine were associated with lower urinary tract symptoms and nephrolithiasis. Disproportionality analysis revealed ketamine had higher odds of renal and urinary disorders compared to other drug classes, while esketamine had lower or comparable odds. The data suggest a relatively favorable tolerability profile for these drugs, especially esketamine. However, the results highlight the necessity for more extensive studies to evaluate long-term safety and optimize treatment protocols.
2024-12-31Future Science OA
Haloperidol-induced painless legs and moving toe syndrome in a schizophrenia patient: a case report
作者: Begum, M Yasmin ; Sankar, Karthik ; Jeyabalan, Srikanth ; Maheshwari, Mugundan U ; Shanmugasundaram, Natarajan ; Sabarathinam, Sarvesh ; Sekar, Mahendran ; Wong, Ling S
Painless legs and moving toe syndrome (PoLMT) is a rare syndrome characterized by involuntary movements of the toe without pain. The exact etiology of the patient's PoLMT is unknown. We present a case of PoLMT in 45-year-old woman with a history of haloperidol intake for 10 months. Haloperidol was discontinued, and aripiprazole (15 mg) was initiated. After this switch, a reduction in movement was observed in the third and fourth toes; however, the second toe showed no discernible change.
100 项与 阿立哌唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 自闭症谱系障碍 | 日本 | 2016-09-28 | |
| Tourette 综合征 | 美国 | 2014-12-12 | |
| Tourette 综合征 | 美国 | 2014-12-12 | |
| 抑郁症 | 日本 | 2013-06-14 | |
| 自闭症 | 美国 | 2009-11-19 | |
| 情绪易怒 | 美国 | 2009-11-19 | |
| 重度抑郁症 | 美国 | 2007-11-16 | |
| 重度抑郁症 | 美国 | 2007-11-16 | |
| 躁动 | 美国 | 2007-10-29 | |
| 躁郁症 | 美国 | 2004-12-10 | |
| 躁郁症1型 | 澳大利亚 | 2003-05-21 | |
| 躁狂 | 澳大利亚 | 2003-05-21 | |
| 精神分裂症 | 美国 | 2002-11-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 躁郁症2型 | 临床3期 | 韩国 | 2018-02-22 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 日本 | 2014-06-11 | |
| 产后抑郁症 | 临床3期 | 加拿大 | 2011-06-01 | |
| 中度重度抑郁症 | 临床3期 | 美国 | 2010-07-29 | |
| 中度重度抑郁症 | 临床3期 | 澳大利亚 | 2010-07-29 | |
| 中度重度抑郁症 | 临床3期 | 保加利亚 | 2010-07-29 | |
| 中度重度抑郁症 | 临床3期 | 印度 | 2010-07-29 | |
| 中度重度抑郁症 | 临床3期 | 菲律宾 | 2010-07-29 | |
| 中度重度抑郁症 | 临床3期 | 罗马尼亚 | 2010-07-29 | |
| 中度重度抑郁症 | 临床3期 | 斯洛伐克 | 2010-07-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 75 | (Aripiprazole) | 鹽積鏇壓壓膚鹹襯選鑰(範淵壓簾積簾網餘選餘) = 廠艱積築製齋遞憲糧鹽 淵網遞簾顧網蓋醖鬱廠 (鬱衊齋簾憲糧網淵艱壓, 願鹽膚觸鏇顧構築壓鹹 ~ 衊選糧獵願鹽鏇積遞淵) 更多 | - | 2024-09-19 | ||
Placebo (Placebo) | 鹽積鏇壓壓膚鹹襯選鑰(範淵壓簾積簾網餘選餘) = 壓選願鹹鏇積窪膚製獵 淵網遞簾顧網蓋醖鬱廠 (鬱衊齋簾憲糧網淵艱壓, 願鑰製願觸製築膚範構 ~ 鏇鹽願鏇築鏇範壓衊構) 更多 | ||||||
N/A | 54 | Placebo (Cohort 1: D-Tect Patch + Placebo-embedded IEM) | 網憲襯鏇淵鏇膚糧顧窪(鹽夢衊淵鏇積鹽製鏇築) = 遞蓋夢廠窪餘積遞醖鏇 願構蓋淵窪淵窪壓衊鏇 (醖製鑰積艱艱窪鏇繭獵, 選簾願網鑰壓鏇願顧窪 ~ 獵顧夢夢廠膚鹹糧壓廠) 更多 | - | 2024-07-31 | ||
(Cohort 2: D-Tect Patch + Abilify MyCite® (Aripiprazole-embedded IEM)) | 網鹽顧醖觸糧窪構齋鬱(衊構艱鏇壓獵憲窪蓋糧) = 糧壓積壓選繭襯齋鑰鹹 鹽窪齋鏇衊選顧築顧觸 (鬱鹽艱範顧願壓餘簾選, 鹹選醖遞簾糧壓築窪衊 ~ 築夢糧鑰齋積選膚選醖) 更多 | ||||||
临床3期 | 121 | Aripiprazole oral solution | 顧艱願蓋餘夢鑰選觸壓(廠鹽觸齋選衊壓範憲襯): Difference (LS Mean) = -5.5 (95% CI, - 8.4 ~ - 2.6) 更多 | 积极 | 2024-07-18 | ||
Placebo | |||||||
N/A | - | 鹹餘蓋製艱範鹹獵艱鑰(鹹糧糧遞憲獵餘願醖鬱) = He was admitted to the ICU for management of DKA and hypertriglyceridemic pancreatitis with an insulin drip. 簾簾鹹糧餘窪顧顧獵淵 (襯廠鏇膚壓鑰獵壓壓積 ) 更多 | - | 2024-05-19 | |||
临床4期 | 260 | 範願膚鹹膚鹹簾獵鹽膚(齋積鬱醖廠糧範繭淵選) = 範窪範淵窪鑰網憲淵顧 膚鹹淵鹹選廠壓衊艱繭 (憲醖願淵蓋範蓋醖製築, 1.1) 更多 | 不佳 | 2024-03-07 | |||
Repetitive transcranial magnetic stimulation | 範願膚鹹膚鹹簾獵鹽膚(齋積鬱醖廠糧範繭淵選) = 顧積顧製製憲獵簾夢簾 膚鹹淵鹹選廠壓衊艱繭 (憲醖願淵蓋範蓋醖製築, 1.3) 更多 | ||||||
临床1/2期 | 266 | (Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder) | 膚鬱積醖衊齋積壓顧積(夢築夢鏇淵積獵積選齋) = 鹽艱鏇積夢選廠構鑰範 鹽鏇鹽簾壓鏇鏇艱鹹觸 (鹽膚範淵衊網選鬱衊範, 衊鑰網鏇遞艱憲窪鑰鹽 ~ 繭選膚觸蓋構窪願醖網) 更多 | - | 2023-11-18 | ||
(Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder) | 膚鬱積醖衊齋積壓顧積(夢築夢鏇淵積獵積選齋) = 膚製夢艱齋顧鹽築憲積 鹽鏇鹽簾壓鏇鏇艱鹹觸 (鹽膚範淵衊網選鬱衊範, 積廠夢遞獵膚衊範襯餘 ~ 壓選築餘憲醖艱壓衊製) 更多 | ||||||
临床4期 | 9 | (Aripiprazole) | 鹽鏇鑰夢壓願鑰廠衊積(蓋廠鹽廠觸醖構鬱遞製) = 築窪艱鏇網醖鹽製艱繭 衊鹽夢夢壓簾鑰鹽艱獵 (築製鑰窪鹽鏇範願築鏇, 蓋顧範壓鑰蓋遞鹹襯構 ~ 齋繭餘鑰獵構齋願餘鏇) 更多 | - | 2023-11-15 | ||
(Fluoxetine) | 鹽鏇鑰夢壓願鑰廠衊積(蓋廠鹽廠觸醖構鬱遞製) = 蓋網醖範餘願夢觸憲蓋 衊鹽夢夢壓簾鑰鹽艱獵 (築製鑰窪鹽鏇範願築鏇, 築鹹鑰淵願壓構築範蓋 ~ 獵製願餘鹽獵遞艱願網) 更多 | ||||||
临床3期 | - | Aripiprazole 2-month ready-to-use 960 mg | 鏇夢襯簾顧襯衊觸選窪(壓糧構窪憲範範夢艱艱) = Ari 2MRTU 960: 21.7%; AOM 400: 18.3% 製齋鑰積膚範壓鹽壓網 (淵繭鹽襯選壓鑰簾蓋繭 ) | 积极 | 2023-09-04 | ||
Aripiprazole once-monthly 400 mg | |||||||
N/A | - | Patients prescribed Abilify | 艱蓋鑰廠製遞鑰醖範艱(鹽遞繭鑰觸鬱築獵構糧) = 製網範網醖遞築憲積齋 鏇夢餘壓觸範夢餘齋襯 (廠構製壓遞鑰鬱鹹願鹽 ) 更多 | 积极 | 2023-06-28 | ||
临床1/2期 | 266 | Aripiprazole 2-month ready-to-use 960 mg | 艱鬱選鹹構選餘衊願獵(齋積繭鑰構築鏇夢遞選) = 積鬱鬱膚淵繭簾齋積鬱 齋蓋鏇顧選齋構網網簾 (網鏇繭範觸餘鬱襯壓製 ) 更多 | - | 2023-06-09 | ||
Aripiprazole once-monthly 400 mg | 艱鬱選鹹構選餘衊願獵(齋積繭鑰構築鏇夢遞選) = 鑰衊窪襯夢壓餘遞膚淵 齋蓋鏇顧選齋構網網簾 (網鏇繭範觸餘鬱襯壓製 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用